Skip to Content

'
Eduardo Vilar-Sanchez, MD, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Affiliate Faculty, Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member, Human and Molecular Genetics Graduate Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX
Regular Member, Bioinformatics and Systems Biology Graduate Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Research Interests

  1. Molecular biology of premalignant intestinal polyps and intestinal carinogenesis.
  2. Molecular classification of colorectal cancer.
  3. Mouse models of colorectal cancer and cross-species comparisons.
  4. Hereditary Colorectal Cancer Syndromes: Lynch Syndrome and Familial Adenomatous Polyposis.
  5. Chemoprevention Drug Development.

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler St
Unit Number: 1360
Houston, TX 77030
Room Number: CPB6.3526

Education & Training

Degree-Granting Education

2009 University Miguel Hernandez, Alicante, Spain, PHD, Cum Laude, Honors, Molecular Biology
2007 Spanish National Cancer Center (CNIO), Madrid, Spain, MS, Molecular Oncology
2002 University Miguel Hernandez Medical School, Alicante, Spain, MD, Medicine

Postgraduate Training

12/2009-12/2011 Clinical Fellowship, Hematology/Oncology, University of Michigan, Ann Arbor, MI, Francis P. Worden, MD
7/2007-11/2009 Research Fellowship, Molecular Medicine & Genetics, University of Michigan, Ann Arbor, MI, Stephen B. Gruber, MD, PhD, MPH
6/2004-6/2007 Clinical Residency, Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain, Javier Cortes, MD, PhD
6/2003-6/2004 Clinical Internship, Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain, Javier Cortes, MD, PhD

Honors and Awards

2011-2012 Young Investigator Award, American Society of Clinical Oncology
2011 Extraordinary Award for PhD dissertations, Miguel Hernandez University, Alicante, Spain
2010 Excellence in Research Award, Hematology/Oncology Fellowship Program, University of Michigan
2009 Merit Award, American Society of Clinical Oncology
2009 Outstanding Research Award, Internal Medicine Research Symposium, University of Michigan
2008 Merit Award, American Society of Clinical Oncology
2007-2009 'la Caixa' Fellowship, 'la Caixa' Foundation, Barcelona, Spain
2002 Academic Grant for Undergraduate Students, Department of Anatomy & Histology, Miguel Hernandez University, Alicante, Spain

Selected Publications

Peer-Reviewed Original Research Articles

1. Kneuert PJ, Chang GJ, Hu CY, Rodriguez-Bigas MA, Eng C, Vilar E, Skibber JM, Feig BW, Cormier JN, You YN. Are Young Adults with Colon Cancer Being Over-treated? More Intense Treatments Are Unmatched By Survival Gains. JAMA Surgery. In Press.
2. Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang Z, Hoff PM, Vauthey J, Vilar E, Maru D, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. e-Pub 12/2014. PMID: 25535726.
3. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer. Ann Oncol pii(mdu252):2008-14, 10/2014. e-Pub 7/2014. PMCID: PMC4176451.
4. Vilar E, Mork ME, Cuddy A, Borras E, Bannon SA, Taggart MW, Ying J, Broaddus RR, Luthra R, Rodriguez-Bigas MA, Lynch PM, You YQ. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet 207(10-12):495-502, Oct-Dec, 10/2014. e-Pub 10/2014. PMCID: PMC4278939.
5. Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 25(5):1032-8, 5/2014. e-Pub 2/2014. PMCID: PMC4072907.
6. Bannon SA, Mork M, Vilar E , Peterson SK, Lu K, Lynch PM, Rodriguez-Bigas MA, You YN. Patient-reported disease knowledge and educational needs in Lynch syndrome: findings of an interactive multidisciplinary patient conference. Hered Cancer Clin Pract 12(1):1, 2014. e-Pub 2/2014. PMCID: PMCPMC3922108.
7. Vilar E, Grünwald V, Schöffski P, Singer H, Salazar R, Iglesias JL, Casado E, Cullell-Young M, Baselga J, Tabernero J. A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. Invest New Drugs 30(1):299-305, 2/2012. e-Pub 9/2010. PMID: 20820909.
8. Vilar E, Tabernero J, Gruber SB. Micromanaging the classification of colon cancer: the role of the microRNAome. Clin Cancer Res 17(23):7207-9, 2011, 12/2011. e-Pub 10/2011. PMCID: PMCPMC3422018.
9. Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, Mukherjee B, Iniesta MD, Morgan MA, Rennert G, Gruber SB. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 71(7):2632-42, 2011, 4/2011. e-Pub 2/2011. PMCID: PMCPMC3407272.
10. Dienstmann R, Vilar E , Tabernero J. Molecular predictors of response to chemotherapy in colorectal cancer. Cancer J 17(2):114-26, Mar-Apr, 3/2011. PMID: 21427555.
11. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 10(3):395-403, 2011, 3/2011. e-Pub 1/2011. PMCID: PMCPMC3413411.
12. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9):1794-803, 2010, 9/2010. e-Pub 2/2010. PMID: 20139156.
13. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 7(3):153-62, 2010, 3/2010. e-Pub 2/2010. PMCID: PMCPMC3427139.
14. Vilar E, Mukherjee B, Kuick R, Raskin L, Misek DE, Taylor JM, Giordano TJ, Hanash SM, Fearon ER, Rennert G, Gruber SB. Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res 15(8):2829-39, 2009, 4/2009. e-Pub 4/2009. PMCID: PMCPMC3425357.
15. Vilar E, Scaltriti M, Balmaña J, Saura C, Guzman M, Arribas J, Baselga J, Tabernero J. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer 99(10):1607-12, 2008, 11/2008. e-Pub 10/2008. PMCID: PMC2584960.
16. Durán I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu LL, Yao J, Tabernero J. New drug development in digestive neuroendocrine tumors. Ann Oncol 18(8):1307-13, 8/2007. e-Pub 2/2007. PMID: 17301070.
17. Vilar E, Salazar R, Pérez-García J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 14(2):221-32, 2007, 6/2007. PMID: 17639039.

Invited Articles

1. Vilar E, Calvo E, Tabernero J. Molecular biology of testicular germ cell tumors. Clin Transl Oncol 8(12):846-50, 12/2006. PMID: 17169757.
2. Felip E, Vilar E. The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy. Ann Oncol 17 Suppl 10:x108-12, 9/2006. PMID: 17018710.

Editorials

1. Colbert Maresso K, Vilar E, Hawk ET. Urinary PGE-M in Colorectal Cancer: Predicting More than Risk? Cancer Prev Res (Phila) 7(10):969-72, 10/2014. e-Pub 7/2014. PMCID: PMC4185234.
2. Borras E, Taggart MW, Lynch PM, Vilar E. Establishing a Diagnostic Road Map for MUTYH-Associated Polyposis. Clin Cancer Res 20(5):1061-3, 3/2014. e-Pub 1/2014. PMCID: PMC3996649.
3. You YN, Vilar E . Classifying MMR Variants: Time for Revised Nomenclature in Lynch Syndrome. Clin Cancer Res 19(9):2280-2, 5/2013. e-Pub 3/2013. PMCID: PMCPMC3854938.
4. Vilar E, Tabernero J. Cancer: Pinprick diagnostics. Nature 486(7404):482-3, 6/2012. e-Pub 6/2012. PMID: 22739312.
5. del Campo JM, Vilar E . New challenges for molecular oncology in ovarian carcinoma. Med Clin (Barc) 128(1):15-7, 1/2007. PMID: 17266887.

Abstracts

1. Mork M, You NY, Ying J, Lynch P, Rodriquez-Bigas MA, Vilar E . Elucidating the impact of Hereditary Colorectal Cancer Syndromes in Adolescents and Young Adults ages 35 and under diagnosed with Colorectal Cancer. 18th Annual Meeting Collaborative Group of the Americas Inherited Colorectal Cancer, New Orleans, LA, 9/2014.
2. You NY, Cuddy A, Peterson S, Vilar E , Zorzi D, Mork M, Bannon S, Lynch PM, Rodriguez-Bigas MA. High Prevalence Of Modifiable Lifestyle Risk Factors For Colorectal Cancer Among Lynch Syndromes Patients. 18th Annual Meeting Collaborative Group of the Americas Inherited Colorectal Cancer, New Orleans, LA, 9/2014.
3. Lima Pereira AA, De Mendonga Rego JF, Morris VK, Overman MJ, Cathy Eng C, Garrett CR, Ferrarotto R, Lee MS, Jiang Z, Hoff PM, Vauthey JN, Vilar E , Maru DM, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. J Clin Oncol 32(suppl 3; abstr 494) (#494), 5/2014.
4. Lee MS, Overman MJ, Maru DM, Jiang Z, Manue Sl, Eng C, Kee BK, Fogelman DR, Garrett CR, Advani SM, Vilar E , Shureiqi I, Wolff RA, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. J Clin Oncol 32(5s) (#3633), 5/2014.
5. Hassabo HM, Sahin IH, Al Kazmi SM, Al Mutar SS, Gomes DBD, Pini TM, Vilar E , Dasari A, Kopetz S, Overman MJ, Eng C, Kee BK, Vauthey JN, Hassan M, Garrett CR. Associations between patient (pt) colorectal cancer (CRC) tumor KRAS and BRAF mutation (mut) status and overall survival (OS). J Clin Oncol 32(suppl 3; abstr 473) (#473), 5/2014.
6. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton L, Manuel S, Garrett CR, Vilar E , Dennis CS, Shureiqi I, Mills GB, Shaw KR, Hamilton SR, Wolff RA, Meric-Bernstam F, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. J Clin Oncol 32(5s) (#3619), 5/2014.
7. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton L, Manuel S, Garrett CR, Vilar E , Pini TM, Shureiqi I, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastics colorectal cancer trials: The ATTACC program experience. J Clin Oncol 32(suppl 3; abstr 450) (#450), 5/2014.
8. Morelli MP, Overman MJ, Vilar E , Morris VK, Shureiqi I, Garrett CR, Fogelman DR, Singh Raghav KP, Kee BK, Deaton L, Eng C, Wolff RA, Sebisanovic D, Siew L, Zapanta A, Mei G, Schiller B, Eltoukhy H, Talasaz A, Kopetz S. Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients. J Clin Oncol 32(5s) (#11117), 5/2014.
9. Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR, Dasari A, Singh Raghav KP, Vilar E , Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, Luthra R, Routbort M, Maru DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol 32(5s) (#3509), 5/2014.
10. San Lucas FA, Fowler J, Kopetz S, Vilar E , Scheet P. Drug repositioning with a bioinformatics platform that integrates the TCGA, cMap, and CCLE. 2014 AACR Annual Meeting, San Diego, CA (#5371), 4/2014.
11. Borras-Flores E, Calhoun K, Bhatia G, Wu H, Vilar E . PIK3CA mutation status is not involved in the response of nonsteroidal anti-inflammatory drugs in colorectal cancer cell lines. AACR Annual Meeting, San Diego, CA (#2126), 4/2014.
12. Vilar E , You YN, Vornik LA, Stoffel EM, Lim RM, Lipkin SM, Perloff M, Brown P. A phase lb biomarker trial of naproxen in patients at risk for DNA mismatch repair deficient colorectal cancer. AACR: Frontiers in Cancer Prevention Research:C52, 10/2013.
13. Vilar E , Bannon S, Mork M, Cuddy A, Lynch PM, You YN. Colorectal Cancer in Lynch Syndrome: No Age Discrimination. 2013 INSIGHT Meeting, 8/2013.
14. You NY,Chang GJ, Bannon S, Mork M, Vilar E , Cuddy A, Lynch PM, Rodriguez-Bigas MA. Lynch Sydrome Associated Rectal Cancer: Characteristics and Outcomes. 63rd Annual Meeting of the Society of Pelvic Surgeons, 7/2013.
15. Vilar E , Wu W, Bhatia G, Cuddy A, Mork MM, Bannon SA, et al. Can microsatellite status of colorectal cancer (CRC) be reliably assessed after neoadjuvant therapy?. J Clin Oncol 31:1525, 6/2013.
16. Morris VK, Overman MJ, Eng C, Vilar E , Morelli M, Jiang Z, et al. Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. J Clin Oncol 31:3632, 6/2013.
17. San Lucas FA, Kopetz S, Scheet PA, and Vilar E . Discovering new therapies for BRAF mutat-like colorectal cancers. J Clin Oncol 31:3623, 6/2013.
18. Morelli MP, Overman MJ, Dasari A, Ali Kazmi SM, Vilar E , Eng C, et al. Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. J Clin Oncol 31:3512, 6/2013.
19. You YN, Vilar E , Slack R, Chang GJ, Nguyen STN, Cuddy A, et al. Lynch syndrome testing in ethnically diverse patients: Mutation spectrum and performance of predicition models. J Clin Oncol 31:1546, 6/2013.
20. Y. Nancy You, Eduardo Vilar , Melissa W. Taggart, Maureen E. Mork, Sarah A. Bannon, Patrick M. Lynch, Miguel A. Rodriguez-Bigas. DNA mismatch repair protein immunohistochemistry in colorectal cancer after neoadjuvant therapy: The pre-treatment biospy should be the standard. 16th Annual Collaborative Group of Americas on Inherited Colorectal Cancer, Boston, MA, 10/2012.
21. M.J. Overman, S. Kopetz, S. Wong, J. Tie, S. Kosmider, A. Jacob, E. Vilar , P. Gibbs, J. Desai, B. Tran. Survival Outcomes in Metastatic Colorectal Cancer (CRC) with High- Level Microsatellite Instability (MSI-H). ESMO Annual Meeting 2012 Vienna, Austria, 9/2012.
22. F.A. San Lucas, P. Scheet, E. Vilar . Clinically assessing colorectal cancers with next-generation sequencing. ICSB: The 13th International Conference on Systems Biology Toronto, Canada, 8/2012.
23. Ivan-Diaz-Padilla, Nuria Romero, Eitan Amir, Xavier Matias-Guiu, Eduardo Vilar , Franco Muggia, Jesus Garcia-Donas. Mismatch Repair Status As A Prognostic Marker In Endometrial Cancer. British Gyanecological Cancer Society Annual Scienific Meeting, The Queen Elizabeth II Conference Centre London, UK, 7/2012.
24. Vilar E , Chow A, Raskin L, Iniesta MD, Mukherjee B, Gruber SB. Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer. J Clin Oncol (Meeting Abstracts) 11028, 5/2009.
25. Raskin L, Johnson TM, Fullen DR, Giordano TJ, Vinco M, Mukherjee B, Ahn J, Vilar E , Gruber SB. HMGA2 is a novel prognostic factor in melanoma. AACR Meeting Abstracts:2604, 4/2009.
26. Vilar E , Mukherjee B, Rennert G, Gruber SB. Discovering new drugs to target microsatellite instable (MSI) colorectal cancer (CRC) using the Connectivity Map (CMap). ASCO Meeting Abstracts:11087, 5/2008.
27. Capdevila-Castillon J, Crespo G, Garcia-Carbonero R, Vilar E , Jimenez-Lacave A, del Prado MPM, et al. Results of the Gastroenteropancreatic NETs Spanish Registry in the 2001-2009 Period. 6th Annual Conference of the European-Neuroendocrine-Tumor-Society:19, 3/2007.
28. Martinez P, Saura C, Perez Garcia JM, Vilar E , Gomez P, Casado E, et al. [Analysis of the accuracy of the Family History in Patients diagnosed with Breast or Colon Cancer]. XI National Congress of the Spanish Society of Medical Oncology:P-20, 49, 2007.
29. Saura C, Dominguez R, Fortuny D, Vilar E , Sabadell D, Cordoba O, et al. [Breast Cancer Early Diagnosis Program in High-Risk Females: Pilot Experience of Surveillance Using Mammography and Breast MRI]. XI National Congress of the Spanish Society of Medical Oncology:O-14, 0, 2007.
30. Garcia-Carbonero R, Vilar E , Alonso V, Martinez del Prado MP, Sevilla I, Crespo G, et al. [Spanish National Tumor Registry of Neuroendocrine Gastroenteropancreatic Tumors: Epidemiology, Paterns of Clinical Practice and Long-Term Survival in our Environment]. XI National Congress of the Spanish Society of Medical Oncology:O-46, 26, 2007.
31. Salazar R, Vilar E , Garcia-Carbonero R, Alonso V, Martinez del Prado M, Sevilla I, et al. 2001-2007 Results of the gastroenteropancreatic NETs Spanish Registry. 4th Annual ENETS Conference, 2007.
32. Vilar E , Scaltriti M, Saura C, Guzman M, Macarulla T, Arribas J, et al. Microsatellite instability (MSI) due to mutation or epigenetic silencing is associated with increased cytotoxicity to irinotecan (CPT-11) in human colorectal cancer (CRC) cell lines. ASCO Meeting Abstracts(10527), 2007.
33. Vilar E , Saura C, Scaltriti M, Guzman M, Balmana J, Macarulla T, et al. Microsatellite instability (MSI) due to mutation or epigenetic silencing is associated with increased cytotoxicity to irinotecan (CPT-11) in human colorectal cancer (CRC) cell lines. Gastrointestinal Cancers Symposium, 2007.
34. Garcia-Carbonero R, Vilar E , Alonso V, Martinez del Prado M, Sevilla I, Crespo G, et al. Patterns of care and outcome of patients with gastroenteropancreatic neuroendocrine tumors (GNETs): Results from a Spanish multi-center hospital-based tumor registry. ASCO Meeting Abstracts:15110, 2007.
35. Lopez-Martin A, Paz-Ares L, Calvo E, Castellano D, Valverde C, Neciosup S, Vilar E , San Antonio B, Garcia-Ribas I, Cortes-Funes H, and Bellmunt J. Phase I study of bi-weekly pemetrexed (P) plus cisplatin (C) in patients with advanced cancer. ASCO Meeting Abstracts:2580, 2007.
36. Gomez P, Vilar E , Saura C, Cortes J, Ocana A, Bellet M, et al. Feasibility of pegfilgrastim as haematopoietic support for dose-dense every-2-week adjuvant chemotherapy in breast cancer. ASCO Meeting Abstracts:18606, 2006.
37. Vilar E , Martinez M, Alonso V, Sevilla M, Sastre J, Castellano D, et al. Influence of first line treatment in the 5 (5yS) and 10-year (10yS) survival outcomes of patients with gastroenteropancreatic neuroendocrine tumors (GNETs): 2001-2005 Spanish task force GNET group. ASCO Meeting Abstracts:14058, 2006.
38. Saura C, Vilar E , Cortes J, Bellet M, Ocana A, Gomez P, et al. Pegfilgrastim induces elevation of serum CA 15-3 in breast carcinoma patients after receiving dose-dense adjuvant chemotherapy. ASCO Meeting Abstracts:8595, 2006.
39. Salazar R, Vilar E , Martínez M, Sastre J, Alonso V, Sevilla M, et al. Preliminary results 2001 – 2005 of the Spanish Registry of the gastroenteropancreatic NETs. 2005 of the Spanish Registry of the gastroenteropancreatic NETs. 3rd Annual ENETS Conference; Prague. Czech Republic, 2006.
40. Salazar R, Vilar E , Sevilla I, Sastre J, Villabona C, Alonso V. [Preliminary results from the Spanish Registry of gastroenteropancreatic neuroendocrine tumors 2001 – 2005]. X Congreso Nacional SEOM, Saragoza, Spain, 2005.
41. Cedres S, Felip E, Prat A, Rojo F, Majo J, Pallisa E, de Gracia J, Vilar E , Parera M, and Baselga J. Comparison of Epidermal Growth Factor Receptor (EGFR) and downstream markers expression in samples from Non-Small-Cell Lung Cancer (NSCLC) patients, at diagnosis and after progression following platinum-based chemotherapy. Ann Oncol:ix245–ix59, 2005.
42. Tabernero J, Casado E, Macarulla T, Ramos J, Martinelli E, Gómez P, Roca JM, Vilar E . Target drug therapies against the epithelial growth factor receptor in metastatic colon cancer. V Congreso Nacional FESEO; Valencia. Spain, 2004.

Book Chapters

1. Vilar E , Zalupski MM. Oncology Boards Flash Review. In: Gastric Cancer. Ed(s) Worden FP, Khoriaty RN. Demos Medical Publishing, LLC: New York, 221, 2013.
2. Maresso KC, Patterson S, Vilar E , Hawk E. Prevention and Screening: risk factors, screening, and chemoprevention. In: Cancers of the Colon and Rectum: A Multidisciplinary Approach to Diagnosis and Management. Ed(s) Benson A, Chakravarthy A, Hamilton S, Sigurdson E. Demos Medical Publishing: New York, 2013. ISBN: 9781936287581.
3. Vilar E, Zalupski MM. Gastric cancer. In: Tumor Board Review. Ed(s) Todd RF, Cooney KA, Hayes TG, Mims MP, Worden FP. Demos Medical: New York, 72-80, 2012.
4. Saura C, Vilar E, Macarulla T, Casado E, Ramos FJ, Capdevila J, Taberno J. Chapter 4: Targeted therapies in gastroesophageal cancer : present and future. In: Gastric Cancer Research Trends. Ed(s) Tompkins MB. Nova Science Publishers: New York, 107-127, 2007. ISBN: 978-1-60021-725-8.
5. Vilar E, Sastre J, Tabernero J. [Chemotherapy and biologic treatments of gastrointestinal neuroendocrine tumors]. In: [Handbook of diagnosis and treatment of Neuroendocrine Tumors. GETNE Group]. GETNE Group, 2006.
6. Carulla J, Vilar E, Saura C. [Assessment of nutricional status]. In: Anorexia and Cachexia Handbook. Ed(s) Casas A, Valentin V, Benavides M, Camps C, Carulla J, González M, Pascual A. SEOM: Madrid, 107 – 120 (chapter in spanish), 2005.

Letters to the Editor

1. Vilar E, Balmaña J, Espín E. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer 106(11):2528-9; author reply 2529, 6/2006. PMID: 16628650.
2. Vilar E, Tabernero J, Casado E, Macarulla T, Ramos FJ, Martinelli E, Saura C. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 28(4):424, 8/2005. PMID: 16062087.

Grant & Contract Support

Title: Clinical Impact of Multi-gene Sequencing Panel Among Young Adults with Colorectal Cancer
Funding Source: Clinical Innovator Award
Role: Collaborator
Principal Investigator: Nancy You
Duration: 1/2015 - 1/2016
 
Title: Elucidating the role of CNOT3 in Colorectal Carcinogenesis
Funding Source: Institutional Research Grant Program
Role: Principal Investigator
Duration: 6/9/2014 - 6/9/2015
 
Title: Discovering New Prevention Strategies for Lynch Syndrome
Funding Source: Feinberg Family Gift
Role: Principal Investigator
Duration: 12/1/2013 - 12/1/2017
 
Title: Discovering New Chemopreventive Approaches in Familial Adenomatous Polyposis
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 12/1/2013 - 11/30/2015
 
Title: A phase Ib biomarker trail of Naproxen in patients at risk for DNA Mismatch Repair Deficient Colorectal Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/20/2013 - 9/19/2017
 
Title: Discovering new Targets for Chemoprevention in Familial Adenomatous Polyposis
Funding Source: Duncan Family Institute
Role: Principal Investigator
Duration: 8/1/2013 - 7/31/2015
 
Title: Research Initiation Funds
Funding Source: U.T. - M.D. Anderson Cancer Center
Role: Principal Investigator
Duration: 1/1/2012 - 8/1/2016
 
Title: Developing Targeted Therapies for Microsatellite Instable Colorectal Cancers
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 1/1/2012 - 12/30/2012

Last updated: 1/26/2015